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Abstract 
Background: Malaria still represents a major health threat, in terms of both morbidity and mortality. Complications 
of malaria present a diversified clinical spectrum, with neurological involvement leading to the most serious related-
conditions. The authors recently encountered a case of a 60-year old Italian man presenting with confusion, language 
disturbances and Parkinson-like syndrome 3 weeks after complete remission from severe Plasmodium falciparum cer-
ebral malaria. Chemical and microbiological analysis revealed aseptic meningitis, diffuse encephalitis and abnormal 
immune-activation. Re-infection and recrudescence of infection were excluded. Further analysis excluded paraneo-
plastic and autoimmune causes of encephalitis. A diagnosis of Post-Malaria Neurological Syndrome (PMNS) was finally 
formulated and successfully treated with high dose of steroids.
Methods: A systematic research of current literature related to PMNS was performed.
Results: 151 cases of PMNS were included, the majority of which occurred after severe P. falciparum infections. Four 
main clinical pattern were identified: 37% of the cases presented as “classical” PMNS, 36% presented as delayed cer-
ebellar ataxia (DCA), 18% resembled acute inflammatory demyelinating polyneuropathy (AIDP), and 8% presented as 
acute disseminated encephalomyelitis (ADEM)-like form. Differentiation between different forms was not always sim-
ple, as clinical and radiological findings frequently overlap. Overall, in almost all of the tested cases, cerebrospinal fluid 
was found pathological; EEG revealed nonspecific encephalopathy in 30% of classical PMNS and 67% ADEM; imaging 
tests were found abnormal in 92% of ADEM-like forms. Pathogenesis remains unclear. An autoimmune mechanism is 
the most corroborated pathogenic hypothesis. Overall, the majority of PMNS cases revert without specific treatment. 
In most severe forms, high dose steroids, intravenous immunoglobulins, and plasmapheresis have been shown to 
improve symptoms.
Conclusions: PMNS is a disabling complication of malaria. The overall incidence is not known, due to frequent mis-
diagnosis and under-reporting. Pathogenesis is not also fully understood, but rapid response to immune-modulating 
treatment along with similarities to auto-immune neurological disease, strongly support a dysregulated immunologi-
cal genesis of this condition. The lack of randomized controlled studies regarding therapeutic approaches is a major 
unmet need in this setting. A systematic collection of all the PMNS cases would be desirable, in order to increase 
awareness of this rare condition and to prospectively investigate the most appropriate management.
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Background
According to the World Health Organization (WHO) 
report, in 2018 there were 228 million cases of malaria 
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by approximately 50% in the last decade, the estimated 
number of deaths attributed to malaria was 405,000 in 
2018, with the highest burden among children living in 
endemic countries [1].
At the onset of disease malaria can present with multi 
organ involvement and different clinical spectrums. 
Nervous system complications can occur during both the 
acute infection and the convalescence stage, with cerebral 
malaria (CM) being the most severe form, especially in 
severe complicated cases. Despite appropriate treatment, 
permanent and insidious sequelae have been described in 
1–3% of the adult cases up to 10% in children. Nonethe-
less, neurological complications can occur even in non-
complicated forms [2–4].
Post-Malaria Neurological Syndrome (PMNS) is a 
post-infectious complex neurological entity occurring 
from 2 days up to 2 months after occurrence of malaria. 
According to clinical and laboratory features, four main 
patterns have been suggested: (1) Delayed cerebellar 
ataxia (DCA); (2) Acute inflammatory demyelinating 
polyneuropathy (AIDP)-like syndrome; (3) Acute dis-
seminated encephalomyelitis (ADEM)-like syndrome; (4) 
“Classical” post-malaria neurological syndrome (PMNS) 
[5]. Table 1 provides a detailed description of each form.
Notwithstanding, the identification of these clinical 
patterns is not always simple, due to lack of universally 
accepted definitions, along with a high level of over-
lap between certain patterns. For example, ADEM-like 
and PMNS-like patterns share multiple overlapping fea-
tures, such as multifocal white matter lesions, at times 
spontaneous recovery, and good response to immune-
suppressive therapy. To this extent, imaging is possibly 
more significant for detecting ADEM-like forms rather 
than PMNS-like ones [6]. Furthermore, both DCA and 
AIDP may occur as part of CM as well as in post-malaria 
illness. The differential diagnosis between PMNS and 
CM- related illness relies on the time of onset and the 
presence of parasitaemia [7, 8]. It should be also pointed 
out that, apart from these main four patterns, PMNS 
could anecdotally manifest with isolated non-specific 
neuropsychiatric features, generalized myoclonus and 
postural tremors [9, 10].
This manuscript focuses on a case of severe PMNS, 
occurring 20  days after an episode of cerebral malaria 
due to Plasmodium falciparum. A systematic review on 
PMNS in literature has been conducted as well, as to pro-
vide some hints for further studies.
Case report
On October, 20th, 2019, a 60-year old previously healthy 
Caucasian man was admitted to the Emergency Depart-
ment (ED) of University Hospital of Udine (North East 
Italy) with a comatose condition after 4 days of persistent 
fever, confusion, and agitation.
He was employed as a road projector in Ouagadougou, 
Burkina Faso, where he used to spend almost 9 months 
per year throughout the last 30 years. He reported expe-
riencing many episodes of non-complicated P. falciparum 
malaria throughout his life (malaria diagnosis was estab-
lished in the local medical centre in Africa by means of 
Rapid Diagnosic Tests, RDTs), for which he was treated 
with an artemisinin-based combination therapy. Never-
theless, he always refused to use anti-malarial chemopro-
phylaxis out of personal choice.
A diagnosis of cerebral P. falciparum malaria was for-
mulated in the ED by means of the RDT and blood smear 
(parasitaemia of 2.5%). No other criteria of cerebral 
malaria were present.
The patient was subsequently admitted to the Intensive 
Care Unit, where he underwent orotracheal intubation, 
life support therapy, and intravenous (IV) treatment with 
artesunate. Within two days, his neurological condition 
Table 1 Suggested PMNS main patterns
PMNS pattern Clinical presentation and definition
Delayed cerebellar ataxia (DCA) An acute onset self-limiting ataxia, without any other neurological symptoms. It was the 
first type of post-malaria neurological complication to be described
Acute inflammatory demyelinating polyneuropathy (AIDP)-
like, namely Guillain Barré Syndrome
An acute ascending areflexic weakness, with or without sensory impairment. Cranial 
nerves might be affected, as well (viz. Miller Fisher Syndrome). In our review AIDP-like 
forms were defined according to Brighton criteria, as the presence of: a) acute onset 
of bilateral symmetric flaccid paralysis of the limbs and/or of cranial nerve inner-
vated muscles with or without involvement of autonomic system; b) impaired deep 
tendon reflexes in affected limbs; c) monophasic pattern; d) absence of an alternative 
diagnosis
Acute disseminated encephalomyelitis (ADEM)-like syndrome An autoimmune multifocal demyelinating illness. It can be sometimes associated to 
autoimmune encephalitis and seizures
“Classical” post-malaria neurological syndrome (PMNS) A self-limiting encephalopathy whose clinical presentation is not included in the 
previously described syndromes. Classical PMNS scenario may present both motor, 
sensorial, and psychiatric symptoms
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rapidly improved. Plasmodium clearance was docu-
mented after 48 h of IV therapy by means of blood smear. 
On day 3 the treatment was switched to oral dihydroarte-
misinin-piperaquine for another 3 days. The patient was 
then discharged on day 7.
On November 10th, (13  days post discharge), the 
patient woke up from sleep with high fever, intense 
headache, and acute confusion. His wife reported hav-
ing noticed abrupt onset of shaking tremors and spatial–
temporal disorientation in the morning.
In the ED his body temperature was 39  °C, his blood 
pressure was in the normal range limits, and his cardiac 
frequency was 107 beats per minute. He was agitated, 
and his sensorium went through different stages of con-
sciousness (his Glasgow Coma Scale score went from 9 to 
13 in between the phases).
Physical examination revealed normal pupil reactivity. 
No cranial nerve palsy was noted. His body was shaken 
by intense postural tremors. Neck stiffness was also 
present. A more specific neurological examination was 
difficult to perform due to the state of consciousness. 
He went from staring and mute, to aggressive behav-
iour within few minutes. He was severely confused, and 
exhibited slurred speech.
Biochemical laboratory data showed normal values, 
as well as the inflammation parameters (including pro-
tein C reactive, PCR and procalcitonin-PCT). No signs 
of meningeal irritation were observed. Recrudescence 
of malaria was immediately excluded through RDT, lin-
ear-amplification mediated PCR (LAMPCR) and blood 
smear. Cerebrospinal fluid (CSF) analysis at admission 
revealed a slightly elevated protein level (737 mg/L), and 
moderate lymphocytic pleocytosis (16 cells/µL, 64% lym-
phocytes), with normal glucose levels. Oligoclonal bands 
(OCBs) type 3 were also found positive. CSF autoimmune 
panel was performed, and no auto-antibody was found.
Bacterial, mycobacterial and fungal examination of 
both CSF and blood yielded negative results; multi-
plex polymerase chain reaction (FilmArray Meningitis/
Encephalitis panel bioMérieux, Marcy l’Etoile, France) 
for bacterial, viral and fungal agents causing meningitis 
and/or encephalitis was negative (Table 2 shows FilmAr-
ray panel results). Blood and urine cultures turned out 
negative. Serological and molecular analysis excluded 
further major infectious causes of fever and central nerv-
ous system infection as well (Trypanosoma, Leptospira, 
Borrelia spp, Rickettsia, Leishmania, Brucella, Erhlichia, 
Treponema).
Nevertheless, multiple viral serologies yielded posi-
tive results, including IgM and IgG for EBV, CMV, HIV, 
West Nile Virus, Chikungunya, and Thick Born enceph-
alitis. The autoimmune test panel also showed positiv-
ity for antinuclear antibodies (ANA) with 1:1280 titre, 
along with low titres of anti-Jo1, and anti Scl70. These 
results were interpreted as false positive results due to 
a probable cross-reaction attributable to polyclonal B 
lymphocyte activation.
Electroencephalogram (EEG) showed a diffuse slow 
activity, with no specific pattern. Computerized tomog-
raphy (CT) scan of the head and magnetic resonance 
(MRI) were normal. Whole body imaging investiga-
tions through CT scan, testicular echography and 
18F-fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography/computed tomography (PET/CT) 
were also performed, to exclude any paraneoplastic 
aetiology.
On day 5, the patient’s neurological condition suddenly 
declined, with accentuation of four-limb tremors, and 
occurring of facial and buccal fasciculation, dysgraphia, 
dysphasia with aggressive and incomprehensible lan-
guage, hallucinations, and refractory insomnia. Physical 
examination also revealed bradykinesia, Parkinson-like 
gait, and postural instability.
CM recurrence or recrudescence was once again 
excluded by means of RDT, LAMPCR and blood smear. 
A second lumbar puncture showed a significant increase 
of CSF cell count (47/µL), with predominance of poly-
morphonuclear elements (80%), and higher protein 
Table 2 Infectious and  autoimmune tests on  CSF 
Microbiological data
Direct microscopic analysis Negative
Culture Negative
FilmArray Meningitis/Encephalitis (ME) panel (bioMérieux, Marcy 
l’Etoile, France)
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concentration (1188  mg/L). Microbiological panel test 
was confirmed negative.
A diagnosis of PMNS was finally elaborated and IV 
methylprednisolone was started at the dose of 1  g/day 
for three days; then the dose was tapered over 4  weeks 
by oral route. CSF was re-checked on day 10, finding 
complete normalization of cell count and slight residual 
hyperproteinorrachia. The neurological condition dra-




A systematic research of current literature related to 
PMNS was conducted from January, 1970 to Octo-
ber, 2020. The following keywords and MeSH terms 
were employed: “Post-malaria neurological syndrome”; 
post-malaria[All Fields] AND neurological[All Fields] 
AND ("syndrome"[MeSH Terms] OR "syndrome"[All 
Fields]);Postmalaria neurological syndrome; Post-malaria 
ADEM; post[All Fields] AND ("malaria"[MeSH Terms] 
OR "malaria"[All Fields]) AND ("encephalomyelitis, acute 
disseminated"[MeSH Terms] OR ("encephalomyelitis"[All 
Fields] AND "acute"[All Fields] AND "disseminated"[All 
Fields]) OR "acute disseminated encephalomyelitis"[All 
Fields] OR "adem"[All Fields]); Post malaria DCA; 
post[All Fields] AND ("malaria"[MeSH Terms] OR 
"malaria"[All Fields]) AND DCA[All Fields]; Post-
malaria neurological; postmalaria[All Fields] AND 
neurological[All Fields]; Acute inflammatory demyeli-
nating polineuropathy after malaria, Acute[Title] AND 
disseminated[Title] AND encephalomyelitis[Title] AND 
malaria[Title]. The reference databases were: Med-
line, Pubmed, and Embase. Data from abstracts, poster 
presentations at congresses, and guidelines were also 
included. Appendix 1 summarizes the details of Data 
sources.
Terms and definitions
Malaria infection: the presence of malaria parasites in the 
blood confirmed by microscopic examination, regardless 
of the presence or absence of clinical symptoms [1].
Severe malaria: a malaria infection presenting with 
signs and/or symptoms of severity and/or evidence of 
vital organ dysfunction [1].
Cerebral malaria: severe P. falciparum malaria occur-
ring with coma (Glasgow coma scale < 11 or Blantyre 
coma scale < 3) and/or coma persisting for more than 
30 min after seizure.
PMNS: neurological or psychiatric symptoms occur-
ring in a time-interval from 2 days up to 60 days after a 
malaria episode, whose parasitaemia have been com-
pletely cleared at the time of PMNS occurrence [4].
PMNS syndromes: no specific case definition exists for 
each of the four syndrome. In this review, the cases have 
been grouped according to current literature regarding 
both malaria and non-malaria settings. See Table  1 for 
full definitions.
Study selection
Overall, 202 records were identified and screened. The 
publications were evaluated independently by each 
reviewer, as to exclude duplicated articles, those that 
were non-pertinent to the review and those not meet-
ing the case definition of PMNS (e.g. neurological enti-
ties occurring during acute parasitaemia). Manuscripts in 
languages other than English, Italian, French, Portuguese, 
and Spanish were not included as well. Overall, 77 publi-
cations were included in the current review.
Results
This systematic review included 151 cases of PMNS, the 
majority of which occurred in form of classical PMNS 
(37%, 56 cases) and DCA (36.4%, 55 cases). AIDP and 
ADEM represented only a small part of the collected 
PMNS, respectively 18.5% (28 cases), and 8% (12 cases). 
Both adult and children were included.
Table 3 summarizes main clinical and diagnostic find-
ings, treatment, and outcomes data.
Overall, more than half of the patients were males, 
with mean ages of 35 years in classical PMNS, 29 years in 
ADEM, and 32 years in AIDP and DCA. Immune status 
profiles of the patients varied widely. In classical PMNS, 
35.7% (20 patients) were naïve, and 12.5% (7 patients) 
were semi-immune. In ADEM 58.3% of the cases (7 
patients), were naive. Immune status was not specified in 
most of AIDP and DCA cases.
Classical PMNS occurred following P. falciparum 
infection in 96.4% of the cases (54 patients); the major-
ity of these infections had been acquired in South-West 
Asia (23 cases, 41.1%) and Africa (29 cases, 16.2%). 
ADEM mainly occurred following P. falciparum infec-
tions (6 cases, 50%) and Plasmodium vivax infections 
(4 cases, 33.3%). The countries were occurred most fre-
quently were India (6 cases, 50%), and Africa (5 cases, 
41.6%). AIDP was associated with P. falciparum infec-
tion in 78.6% of the cases (22 patients). Plasmodium 
vivax infections occurred in 17.9% (5 patients) of AIDP. 
As for ADEM, most of the malaria infections preceding 
AIDP were acquired in India (12 cases, 46.4%), and Africa 
(11 cases, 29.2%). DCA generally followed P. falciparum 
infections (98.2%, 54 cases out 55), and were mainly 
localized in South-West Asia (76.4%, 42 cases). Mixed 
infections (P. vivax and P. falciparum) were reported in 
a few cases.
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Malaria infection presented as complicated form in 
78.6% (44 cases) of classical PMNS, 66.7% (8 cases) of 
ADEM, and 100% (55 cases) of DCA. Severe malaria 
was reported in only one patient (3.6%) presenting with 
AIDP. Noteworthy, characteristics of malaria infection 
were not clarified for most of AIDP cases.
Clinical manifestations varied widely. Neuropsychi-
atric disturbances were the most frequent symptoms 
in classical PMNS (25%, 14 cases) and ADEM (6 cases, 
50%), whereas they were never reported in either AIDP 
or DCA. Similarly, seizures occurred in almost 70% 
(39 cases) of classical PMNS, and 41.7% (5 cases) of 
ADEM. No seizures were reported in AIDP and DCA. 
Various degrees of motor disturbances were described 
in most forms (including tremors, cranial nerve palsy, 
pyramidal, and cerebellar syndrome). Motor disorders 
occurred in 67.9% (38 cases) of classical PMNS and in 
100% of ADEM, AIDP and DCA.
Instrumental tests showed a low diagnostic yield in 
the majority of the reports. Head magnetic resonance 
(MR) showed non-specific alterations in white mat-
ter in 14.3% (8 cases) of classical PMNS and 91.7% (11 
cases) in ADEM. In most of AIDP and DCA reports, 
instrumental tests were not described. EEG generally 
showed a diffuse encephalopathy with generalized slow 
pattern. Pathological EEG patterns were described in 
28.6% (16 cases) of classical PMNS and 66.7% (8 cases) 
of ADEM. Again, for AIDP and DCA there is a lack of 
information regarding EEG results.
Overall, lumbar puncture was performed and 
described in 53.6% of the cases (81 patients). Abnormal 
physical–chemical composition of CSF was detected in 
84.6% of the “classical PMNS” (44 out of 52 patients), 
88.2% of AIDP (11 out 17 patients) and 100% of the 
ADEM (10 cases out 10). An elevated cell count was 
observed in most cases (predominantly lymphocytes) 
with or without elevated protein concentration lev-
els. In 1 classical PMNS case, intrathecal production 
of IgM was reported [5]. Within the DCA group, CSF 
analysis was performed in one case [11]; no abnormal 
values were reported.
With regards to treatment, the most frequent approach 
was symptomatic. Overall, general supportive measures 
without any specific therapy (such as antipyretics, oxy-
gen therapy and anti-epileptic drugs) were attempted in 
73.2% of the classical PMNS (41 cases), 46.4% of ADEM 
(13 cases), 72.2% of AIDP (13 cases), and 66.7% of DCA 
(2 cases). Among the patients who received specific treat-
ments besides supportive measures, corticosteroids were 
administered in 92% of ADEM (11 patients), 27% of clas-
sical PMNS (15 cases), 11% of AIDP (2 cases) and 66.7% 
(2 patients) of DCA. Furthermore, in AIDP intravenous 
immunoglobulins and plasma exchange methods were 
administered and employed in 11.1% (2 cases) and 5.3% 
(1 case), respectively.
Fatal outcome was reported in 1.8% of classical PMNS 
(1 case), 5.5% of SCA (3 cases), and 25% (7 cases) of AIDP. 
No deaths were reported in the ADEM group. Almost all 
the survivors fully recovered from classical PMNS and 
ADEM. Various grade of neurocognitive impairment 
and motor sequelae was described in 71.4% of AIDP (20 
cases) and 78.2 (48 cases) of DCA.
Discussion
PMNS has been defined as a complex neurological con-
dition developing within 2  months after fully recovery 
from a malaria episode [4]. The first reports date back to 
1966. Since then a number of case reports and case series 
of PMNS have been described. Incidence rates of PMNS 
has been estimated to range from 1.2 per 1000 cases in 
uncomplicated forms, up to 18 out of 1000 in severe 
forms. PMNS after P. falciparum infections are the most 
frequently reported [4]. Noteworthy, most of the PMNS 
presenting as ADEM occurred after non-falciparum 
malaria [6], but the reason for this association is not clear.
Clinical presentation
Clinical findings in “classical PMNS” are extremely het-
erogeneous, ranging from acute encephalitis in almost 
80% of the patients, confusion and fever in over half of 
the cases, seizures (33%), language disturbance (about 
30%), tremor (23%), myoclonus (11%), and psychiatric 
illness (17%) [5]. Neurocognitive decline, acalculia, and, 
rarely, autonomic system disorders, ophtalmoplegia and 
cranial nerve palsy have been described as well. DCA is 
most typically characterized by gait ataxia and isolated 
cerebellar syndrome, whereas in ADEM-like forms motor 
impairment in predominant [8, 12].
Diagnostic methods
Overall, instrumental tests seemingly did not represent 
valuable diagnostic tools in any of the described cases. 
In a minority of reports, MR showed nonspecific signal 
uptake in white matter. The most frequent abnormali-
ties are localized in periventricular areas, basal ganglia, 
brain stem, and cerebellum. Spinal cord and optic nerve 
involvement may also occur albeit more rarely [13]. 
Commonly, the diagnosis of ADEM is suggested by MRI 
multifocal, bilateral, asymmetric, white matter abnor-
malities, with hyperintense appearance in T2 and FLAIR 
sequences [14]. Localization of MR lesions is thus unre-
lated to clinical presentation (e.g., ataxia does not neces-
sarily correlates with cerebellar lesions) [8].
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Pathogenesis
An immune-mediated process is the most corroborated 
hypothesis regarding PMNS pathogenesis. Different 
mechanisms have been proposed.
Auto-reacting T-cells could be triggered by a certain 
grade of molecular mimicry and nonspecific activation, 
leading to autoimmune response toward CNS antigens 
[6, 15]. This mechanism is also a well-known prerequisite 
of classical AIE, AIDP and ADEM.
In the wake of the immunologic-theory, same authors 
described a series of PMNS cases developing as classi-
cal autoimmune encephalitis (AIE) mediated by neu-
ronal antibodies against ions channels and synapses. 
Alike AIE, PMNS has been associated to the production 
of N-methyld-aspartate-receptor -NMDAR, antibodies, 
anti-voltage-gated-potassium-channel (VGKC) antibod-
ies, anti neuroanexin α3 antibodies. In these cases, the 
disappearance of autoantibodies and MRI lesions have 
been documented following steroid treatment cycles [16, 
17].
Polyclonal B cell over-activation is another possible 
immunological mechanism. It has been demonstrated 
that Plasmodium-parasitized erythrocytes express sev-
eral membrane microbial immunoglobulin binding pro-
teins (IBPs), which persist over time following parasite 
eradication. Some IBPs, such as P. falciparum erythro-
cyte membrane protein 1 (PfEMP1) extensively bound to 
different circulating human immunoglobulins, thus lead-
ing to direct B-lymphocyte stimulation and subsequent 
secretion of different antibodies [18]. This theory might 
explain the frequent finding of elevated titres of IgG and 
IgM antibodies against multiple viruses during PMNS. 
Despite the exclusion of any concomitant infectious 
disease as underlying cause of the encephalopathy, the 
patient presented various degrees of IgG and IgM posi-
tivity against multiple viruses, low positivity for ANA, 
CSF lymphocytic pleocytosis and intrathecal immuno-
globulin production.
The case study protagonist developed a severe form 
of PMNS characterized by a dramatic neuropsychiat-
ric pattern with abnormal generalized immune-activa-
tion and severe blood brain barrier alteration. Indeed, 
clinical presentation, immunological findings, and rapid 
response to steroids endorsed the immune-mediated 
trigger theory.
Two alternative hypotheses regarding PMNS patho-
genesis have been postulated so far: 1) transient ischae-
mia; 2) cytokine storm.
The ischaemic hypothesis suggests that parasitized red 
blood cells adhere to endothelia and reversibly obstruct 
the brain microvasculature. It has been proposed that 
the higher tendency to cytoadhere of P. falciparum might 
explain the higher prevalence of PMNS in this species 
[19]. Hsieh et  al. reported a case of PMNS where brain 
SPECT revealed decreased radiolabelled agent incorpo-
ration in cerebral hemispheres, hence suggesting impair-
ment of cerebral microcirculation [20, 21]. However, the 
absence of parasitaemia during PMNS and the time laps 
between malaria episodes and post-infectious syndrome 
remains unexplained. Furthermore, an ischaemic gen-
esis is much more compatible with cerebral malaria than 
PMNS.
The cytokine storm hypothesis derived from a single 
in vivo study. de Silva HJ et al. conducted a prospective 
observational analysis in 12 patients with post-malaria 
DCA, reporting significantly higher levels of pro-inflam-
matory cytokines, such as tumour necrosis factor (TNF), 
interleukin 6 (IL-6) and interleukin 2 (IL-2), in both 
serum and CSF, and comparing PMNS affected patients 
to non PMNS affected ones (8 patients). Indeed, TNF lev-
els in CSF have been linked to more severe and disabling 
forms of CM [22, 23]. It has been suggested that TNF 
might play a pathogenic role in CNS damage in CM, by 
possibly promoting parasite sequestration and endothe-
lial activation. A similar role may be hypothesized also in 
PMNS. However, no prospective analysis has been con-
ducted to date in post-malarial disorders.
The role of anti‑malarial treatment
During the past decade, a series of studies suggested that 
the type of anti-malarial treatment could correlate to 
occurrence of PMNS. In particular, the administration of 
mefloquine and atovaquone-proguanil was recognized as 
a risk factor for PMNS [24, 25]. The quinoline anti-malar-
ials (and especially mefloquine) have been associated to 
neurological disorders, both in form of psychiatric symp-
toms, and central anticholinergic syndrome [4]. Some of 
these manifestations overlap with PMNS.
However, to date no significant association of PMNS 
with anti-malarial treatment has been found.
Firstly, quinoline-related effects are self-limiting, and 
they rapidly fade. None of the anti-malarial drugs has 
been related to iatrogenic ADEM-like, AIP, or DCA-like 
toxicity. Furthermore, not all the patients presenting with 
PMNS received quinolines. Notably, most of the cases 
emerged days or weeks after quinoline-withdrawal.
Treatment and outcome
Overall, the majority of PMNS cases revert without 
specific treatment. Prognosis is generally good and no 
long-term sequelae have been described. Several off-
label treatments have been proposed for most severe 
forms. High dose steroids have been administered in 
the majority of the reported cases. Overall, in this revi-
sion 30 patients (19.8%) received steroids, the majority 
of which in the classical PMNS group (15 cases) and the 
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ADEM-like group (11 cases). The most frequently applied 
therapeutic schedule consisted in IV administration of 
either 1 g/day of methylprednisolone or equivalent dos-
age of prednisolone administered over 5–7 doses, and 
subsequent tapering over 4–6  weeks. Alternative dos-
ages included: IV methylprednisolone at 100 mg/day for 
three doses, and tapered for 10 days; oral prednisolone at 
60 mg/day for 4 days without tapering [26, 27]. The first 
schedule was chosen.
In almost all the reported cases, a rapid improvement 
of symptoms was observed upon steroids administration. 
Similarly, the condition of the patient improved rapidly 
after the first dose of corticosteroid and his neurologi-
cal impairment fully reverted after 3 weeks. It has been 
suggested that steroids might hasten the resolution of 
PMNS through anti-inflammatory effect and immune-
suppression, as to turn-off the auto-immune trigger. 
Notably, steroids have been associated to sensible reduc-
tion of serum and CSF concentrations of inflammatory 
cytokines [24]. Nonetheless, the impact of steroid treat-
ment on outcome and sequelae has not been analysed in 
any of the current studies. To date, there is no evidence 
that steroids either ameliorates the prognosis, reduces 
the sequelae, or affect mortality rates in PMNS. Never-
theless, corticosteroids might be harmful in patients suf-
fering of cerebral malaria, as they might increase the risk 
of seizures and gastrointestinal haemorrhages [28]. It is 
not clear whether steroids really changes the course of 
the disease, as some of these forms might have probably 
spontaneously revert without treatment.
Some authors promote the use of intravenous immu-
noglobulins (IV-Ig) in refractory cases as a second 
line therapy. Indeed, IV-Ig have been demonstrated to 
exert beneficial effects by inhibiting and reverting the 
cytoadherence of infected erythrocytes in  vitro [29]. 
Stangel et al. were the first group to report the ability of 
polyclonal immunoglobulins in vitro to modulate nitric 
oxygen production and microglial function in  vitro. 
It has been assumed that IV-Ig modulate the local 
immune response also in CNS [30]. Further modes of 
action of IV-Ig have been attributed to the ability of 
hyperimmune Ig clones to bind and neutralize circulat-
ing antibodies and activated B cells, as well as to mod-
ulate auto-immune response [31, 32]. Marchioni et  al. 
described a case series of 5 patients affected by steroid-
resistant post-infectious (non post-malaria) ADEM and 
myelitis which successfully reverted upon IV-Ig [33]. 
A two patient-case series by Ravaglia et  al. described 
more extensively the IV-Ig role on specific functional 
systems and long-term sequelae, also suggesting a 
potential synergy between IV-Ig and steroids [34]. 
However, both the aforementioned case series included 
patients affected by post-infectious neurological com-
plications, but none of them specifically included cases 
of PMNS (Fig. 1).
Plasmapheresis is another salvage therapy, which could 
be considered in most severe PMNS, in analogy with 
post-infectious encephalitis [26]. In this review, plasma 
exchange was successfully performed in one case of 
severe AIDP after P. falciparum malaria [35, 36].
In summary, there is lack of consensus regarding 
PMNS management. There is currently no available 
data comparing the “watchful waiting strategy”” with 
the immunomodulatory treatments. The actual efficacy 
of steroids, IV-Ig, and plasmapheresis is currently under 
debate.
A course of steroids should be attempted in severe 
non-self limiting forms (e.g. those with no improve-
ment or progressive worsening in few days after the 
presentation). Second-line treatment with IV-Ig should 
be considered for steroid-refractory disease, especially 
as regards “classical” PMNS. A combination of steroids 
Fig. 1 summarizes clinical case-timeline
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and IV-Ig is strongly recommended especially in those 
patients presenting with ADEM-like forms.
To date plasmapheresis has been considered a rescue 
strategy for progressive non-resolving disease. How-
ever, it could be attempted as a first-line treatment for 
AIDP-like forms.
Conclusion
PMNS is a serious complication of malaria. The pre-
cise epidemiology is yet unclear, as diagnosis is often 
subject to misinterpretation due to heterogeneous 
clinical presentation and diagnostic features are hetero-
geneous. Pathogenesis is not also fully understood, but 
rapid response to immune-modulating treatment along 
with similarities to auto-immune neurological disease, 
strongly support a dysregulated immunological genesis 
of this condition.
Aetiologic treatment is not available, but corticos-
teroids, IV-Ig administration, and plasmapheresis 
may offer certain benefits in the most severe cases. 
Clinicians should be encouraged to consider PMNS 
in patients presenting with neurological symptoms 
after a malaria episodes. A systematic collection of all 
the PMNS cases is thus desirable, in order to increase 
awareness of this rare condition and to prospectively 
investigate the most appropriate management.
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